Special Issue

Molecular Research on Novel Anticancer Drugs: From Structure to Molecular Targets

Message from the Guest Editor

Conventional chemotherapeutic drugs are still widely used for cancer treatment. Although most of the currently used anticancer drugs are effective, their administration leads not only to overall toxicity but also to the initiation of metastasis and the development of chemotherapy resistance. Hence, there remains a need for the discovery of new anticancer agents in cancer treatment. Several approaches are relevant to these outlines. One approach is to search for novel anticancer compounds from natural sources (e.g., plants, fungi, microbes, and marine organisms). In contrast, drug repurposing entails using a well-known drug or candidate for a new treatment or medical condition for which it was not previously indicated. Furthermore, the compounds generated by implementing these approaches can serve as starting points for new semi-synthetic or synthetic molecules with anticancer potential. Hence, this Special Issue is open to submissions of recent studies or literature reviews on newly discovered anticancer agents, with a focus on their design, purification/synthesis, characterization, and investigation of their complex molecular mechanisms of action.

Guest Editor

Dr. M. Mizerska-Kowalska
Department of Virology and Immunology, Maria Curie-Sklodowska University, Akademicka 19, 20-033 Lublin, Poland

Deadline for manuscript submissions

30 June 2026

Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/si/266042

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

mdpi.com/journal/cimb

Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/journal/cimb

MDPI

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia
Department of Pathology and Biomedical Science, University of Otago, Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.8 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.